Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Texas Southwestern Medical Center
This is a 72 months long randomized clinical trial longitudinally evaluating beta-cell function, as well as glycemic control and inflammatory markers in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
Age
25–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
type 2 diabetes mellitus diagnosed within the prior 2 months
HbA1c \> 7% at the time of inclusion
willing to perform intensive diabetes management
able to comply with treatment and follow-up regimen
You may not be if
HbA1c \> 8% at time of randomization
creatinine \> 1.5 mg/dl
liver function tests \> 3 times the upper limit of normal
severe anemia
severe proliferative retinopathy
NYHA class III or IV heart failure
active CAD or recent (within 6 months) MI
pregnant, willing to get pregnant, or not willing to practice any contraceptive method
non-english speaking
active heavy alcohol or illicit drug users (within past 6 months)
history of lactic acidosis
Clareo Health | Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
